The report entitled "Global Stem Cell Therapy Market" analyzes the market for stem cell therapy globally, based on product type, therapy type, technology, therapeutic applications, end-user, and region. The report is comprehensive and provides complete historical and projected market size along with trend analysis.
RationalStat offers market share analysis and production capabilities of the leading companies, Covid-19's impact analysis, a competition overview across targeted markets, strategies for market entry, and region of growth potential for the players that are studied in the global stem cell therapy market.

The Market and its Dynamics: Increased R&D efforts by industry players and the government is fueling the global stem cell therapy market

The stem therapy market is anticipated to grow at a rate of approximately 9% over the 2022-2028 forecast period. The constant increase in research and development efforts in stem cell therapies carried out by the major market players will contribute to the development of the stem cell market. R&D initiatives will lead to the development of new and improved products that provide greater protection. It is anticipated that this will attract most people since new products are trustworthy and safe for use. For instance,
• In March 2021, NOVADIP Biosciences S.A. gained FDA approval for its Investigational New Drug (IND) application for its autologous cell treatment product NVD-003. This strategy is expected to boost their market position by improving their product offerings and expanding their consumer base.
• In April 2020, Seneca Biopharma Inc. announced the completion of its new cell manufacturing facility in Suzhou, China. The company will manufacture NSI-566 in this new facility, which is the company’s leading stem cell therapy.
In addition, the development of biotechnology is expected to positively influence the expansion of the market for stem cell therapy as it aids in the development of therapies and tools through modifications and engineering of stem cells. Furthermore, the significant government support and initiatives for research and development in regenerative medicine activities in the developed regions will also boost the market growth.
• For instance, in March 2022, the Medical Research Future Fund (MRFF) launched its Stem Cell Therapies Mission as part of its budget for 2019-20. Around US150 million dollars was allotted by the Australian government to fund research and development of safe and effective drugs for patients of all kinds.

Segmental Analysis

• In terms of therapy type, allogeneic stem cell therapy has a significant share of the market and is predicted to keep its position in the coming years. This is primarily due to the application of allogeneic stem cells for the treatment of different types of cancer such as leukemia, lymphomas, and myelomas because of their graft-vs.-cancer effect.
• According to therapeutic application, oncology segment is expected to hold an impressive share in the global market since stem cell therapy has applications for treating various cancers. Other departments such as Orthopedic, Neurology, Cardiovascular & Myocardial Infraction and Hematology have a large share of the market for stem cell therapy.
• Based on the region, North America dominates the global market for stem cell therapy due to the rapid growth of research and development initiatives, paired with the constant support of the government. Other regions such as Europe and the Asia Pacific are expected to increase significantly over the forecast period.

Competition Analysis: Increasing number of clinical trials and R&D activities to lead the growth of the global stem cell therapy market in the upcoming years
Due to the presence of many well-established companies in the global stem cell therapy market, there is intense competition in the global stem cell therapy market. The global stem cell therapy market is expected to witness a pool of export opportunities due to the increasing prevalence of chronic diseases and increasing cases of cancer, growing awareness of the global population about preventive healthcare, and gradually improving healthcare infrastructure.
Regulatory approvals, manufacturing expansion, and innovation in therapies are the key industrial activities observed in the global stem cell therapy market. Significant consolidation is expected in the global stem cell therapy market during the forecasting period 2022-2028.
• In March 2021, NOVADIP Biosciences S.A. gained FDA approval for its Investigational New Drug (IND) application for its autologous cell treatment product NVD-003. This strategy is expected to boost their market position by improving their product offerings and expanding their consumer base.
• In April 2020, Seneca Biopharma Inc. announced the completion of its new cell manufacturing facility in Suzhou, China. The company will manufacture NSI-566 in this new facility, which is the company’s leading stem cell therapy.
Some of the prominent players operating in the market include Celgene Corp. (Bristol Myers Squibb), ReNeuron Group PLC, BioTime Inc., Mesoblast Ltd., Seneca Biopharma Inc., Opexa Therapeutics Inc., Pluristem Therapeutics Inc., STEMCELL Technologies Inc., ThermoGenesis Holdings Inc., Astellas Pharma Inc., and Caladrius Biosciences Inc. among others.

RationalStat has segmented the global stem cell therapy market on the basis of product, therapy type, technology, therapeutic application, end-use, and region.
• By Product
o Adult Stem Cells (ASCs)
 Hematopoietic
 Mesenchymal
 Neural
 Others (Epithelial/Skin)
o Human Embryonic Stem Cells (HESCs)
o Induced Pluripotent Stem Cells (iPSCs)
o Very Small Embryonic-Like Stem Cells
• By Therapy Type
o Allogeneic Stem Cell Therapy
o Autologous Stem Cell Therapy
• By Technology
o Cell Acquisition
 Bone Marrow Harvest
 Umbilical Blood Cord
 Apheresis
o Cell Production
 Therapeutic Cloning
 In-vitro Fertilization
 Cell Culture
 Isolation
o Cryopreservation
o Expansion and Sub-culture
• By Therapeutic Application
o Oncology
o Orthopedic
o Neurology
o Cardiovascular & Myocardial Infraction
o Hematology
o Others (Wounds & Injuries, Liver Disorders, Diabetes, etc.)
• By End Use
o Hospitals
o Research Organizations
• By Region
o North America
 US
 Canada
o Latin America
 Brazil
 Mexico
 Rest of Latin America
o Western Europe
 Germany
 UK
 France
 Spain
 Italy
 Rest of Western Europe
o Eastern Europe
 Russia
 Poland
 Rest of Eastern Europe
o Asia Pacific
 China
 Japan
 India
 South Korea
 Australia
 ASEAN (Indonesia, Vietnam, Malaysia, etc.)
 Rest of Asia Pacific
o Middle East & Africa
 GCC
 South Africa
 Turkey
 Rest of the Middle East & Africa

For more information about this report https://store.rationalstat.com/store/global-stem-cell-therapy-market-investment-growth-opportunity-analysis/
About RationalStat LLC
RationalStat is an end-to-end US-based market intelligence and consulting company that provides comprehensive market research reports along with customized strategy and consulting studies. The company has sales offices in India, Mexico, and the US to support global and diversified businesses. The company has over 80 consultants and industry experts, developing more than 850 market research and industry reports for its report store annually.
RationalStat has strategic partnerships with leading data analytics and consumer research companies to cater to the client’s needs. Additional services offered by the company include consumer research, country reports, risk reports, valuations and advisory, financial research, due diligence, procurement and supply chain research, data analytics, and analytical dashboards.
Contact
RationalStat LLC
Kimberly Shaw, Content and Press Manager
[email protected]
Phone: +1 302 803 5429